Welcome to Cynthia Danquah Group

Antibiotic-resistant Mycobacterium tuberculosis strains are jeopardizing efforts in eradicating the global Tuberculosis crisis. Mycobacterium tuberculosis is inherently resistant to many antibiotics limiting the number of compounds accessible for therapy. This inherent resistance is caused by several mechanisms.

A key goal of our drug discovery research is tackling antimicrobial resistance through the identification of bioactive compounds from plants that have the potential to become therapeutic agents in the treatment of tuberculosis. Our team leverages core expertise in assay development, high-throughput screening, hit-to-lead medicinal chemistry and in vivo pharmacology to expedite the drug discovery process.

Research Focus Areas

Gemini_Generated_Image_vb38bvvb38bvvb38

Antibiotic Resistance & Tuberculosis Research

Developing novel antibacterial agents and studying mechanisms of resistance to combat tuberculosis and other drug-resistant bacterial infections.

Gemini_Generated_Image_456ayz456ayz456ahfy

Natural Product Drug Discovery

Exploring medicinal plants and natural compounds to discover new drugs that can address emerging global health threats, particularly antimicrobial resistance.

Gemini_Generated_Image_8w4zd8w4zd8w4zd8

Pharmacology & Toxicology

Investigating the safety, efficacy, and biological activity of natural and synthetic compounds using advanced pharmacological models and high-throughput screening assays.

Gemini_Generated_Image_m7ent4m7ent4m7en

Infectious Diseases & Antimicrobial Stewardship

Advancing research on infectious diseases such as respiratory infections and promoting responsible antimicrobial use within healthcare systems.

Our Research Team

Adisa Ayeley MusahPhD Pharmacology

Nana Kwaku Bugyei BuabengPhD Clinical Pharmacology

Isaac Newton NugbemadoPhD Pharmacology

Theophilius Kwesi NinkyiPhD Pharmacology

Recent Publications

Recent Posts

Upcoming Events

No events found!